Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: A study on behalf of the EBMT cellular therapy & immunobiology working party.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
25
09
2021
accepted:
21
09
2022
revised:
13
09
2022
pubmed:
11
10
2022
medline:
7
1
2023
entrez:
10
10
2022
Statut:
ppublish
Résumé
Donor lymphocyte infusion (DLI) is a treatment option to prevent or treat relapse after allogeneic hematopoietic cell transplantation (HCT). We here report data for 173 patients who received one or multiple DLIs after haploidentical-HCT with post-transplant cyclophosphamide (PTCY) at 47 EBMT centers from 2009 to 2018. Indication for DLI was: prophylactic for 59 (34.3%), preemptive for 20(11.6%), and therapeutic for 93(54.1%). For the prophylactic group, the median number of DLIs was 1 (IQR:1-2.5) with a median first dose of 0.1 × 10
Identifiants
pubmed: 36216975
doi: 10.1038/s41409-022-01839-8
pii: 10.1038/s41409-022-01839-8
doi:
Substances chimiques
Cyclophosphamide
8N3DW7272P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
54-60Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Wu X, Liu Q. Prophylaxis and treatment of relapse after haploidentical stem cell transplantation: What is known vs unknown? Semin Hematol. 2019;56. https://doi.org/10.1053/j.seminhematol.2019.04.001 .
Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041–50. https://doi.org/10.1182/blood.v86.5.2041.bloodjournal8652041
doi: 10.1182/blood.v86.5.2041.bloodjournal8652041
Schmid C, Labopin M, Nagler A, Bornhäuser M, Finke J, Fassas A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: A retrospective risk factors analysis and comparison with other strategies by the EBMT acute leukemia working party. J Clin Oncol. 2007;25:4938–45. https://doi.org/10.1200/JCO.2007.11.6053
doi: 10.1200/JCO.2007.11.6053
De Vos J, Baudoux E, Bay JO, Calmels B, Cras A, El Cheikh J, et al. Donor Lymphocyte Infusions (DLI): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Bull Cancer. 2019;106:S35–9. https://doi.org/10.1016/j.bulcan.2018.10.002
doi: 10.1016/j.bulcan.2018.10.002
Schmid C, Labopin M, Schaap N, Veelken H, Brecht A, Stadler M, et al. Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia. Bone Marrow Transpl. 2022;57:215–23. https://doi.org/10.1038/s41409-021-01515-3
doi: 10.1038/s41409-021-01515-3
Gu Z, Wang L, Yuan L, Huang W, Li M, Guan L, et al. Similar outcomes after haploidentical transplantation with post-transplant cyclophosphamide versus HLA-matched transplantation: A meta-analysis of case-control studies. Oncotarget. 2017;8:63574–86. https://doi.org/10.18632/oncotarget.18862
doi: 10.18632/oncotarget.18862
Dholaria B, Savani BN, Labopin M, Luznik L, Ruggeri A, Mielke S, et al. Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: Consensus recommendations from the Acute Leukemia Working Party of the EBMT. Haematologica. 2020;105:47–58. https://doi.org/10.3324/haematol.2019.219790
doi: 10.3324/haematol.2019.219790
Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica. 2007;92:414–7. https://doi.org/10.3324/haematol.10570
doi: 10.3324/haematol.10570
Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H, et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood. 2012;119:3256–62. https://doi.org/10.1182/blood-2011-09-380386
doi: 10.1182/blood-2011-09-380386
Yang L, Tan Y, Shi J, Zhao Y, Yu J, Hu Y, et al. Prophylactic modified donor lymphocyte infusion after low-dose ATG-F-based haploidentical HSCT with myeloablative conditioning in high-risk acute leukemia: a matched-pair analysis. Bone Marrow Transpl. 2020;56:664–72. https://doi.org/10.1038/s41409-020-01088-7
doi: 10.1038/s41409-020-01088-7
Zeidan AM, Forde PM, Symons H, Chen A, Smith BD, Pratz K, et al. HLA-Haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transpl. 2014;20:314–8. https://doi.org/10.1016/j.bbmt.2013.11.020
doi: 10.1016/j.bbmt.2013.11.020
Ghiso A, Raiola AM, Gualandi F, Dominietto A, Varaldo R, Van Lint MT, et al. DLI after haploidentical BMT with post-transplant CY. Bone Marrow Transpl. 2015;50:56–61. https://doi.org/10.1038/bmt.2014.217
doi: 10.1038/bmt.2014.217
Goldsmith SR, Slade M, Dipersio JF, Westervelt P, Schroeder MA, Gao F, et al. Donor-lymphocyte infusion following haploidentical hematopoietic cell transplantation with peripheral blood stem cell grafts and PTCy. Bone Marrow Transpl. 2017;52:1623–8. https://doi.org/10.1038/bmt.2017.193
doi: 10.1038/bmt.2017.193
Jaiswal SR, Zaman S, Chakrabarti A, Sen S, Mukherjee S, Bhargava S, et al. Improved outcome of refractory/relapsed acute myeloid leukemia after post-transplantation cyclophosphamide-based haploidentical transplantation with myeloablative conditioning and early prophylactic granulocyte colony-stimulating factor–mobilized donor lymphocyte infusions. Biol Blood Marrow Transpl. 2016;22:1867–73. https://doi.org/10.1016/j.bbmt.2016.07.016
doi: 10.1016/j.bbmt.2016.07.016
Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the Intensity of Conditioning Regimens: Working Definitions. Biol Blood Marrow Transpl. 2009;15:1628–33.
doi: 10.1016/j.bbmt.2009.07.004
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. In: Bone Marrow Transplantation. 1995, pp 825–8.
Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2003;9:215–33.
doi: 10.1053/bbmt.2003.50026
Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462–5. https://doi.org/10.1182/blood.v76.12.2462.2462
doi: 10.1182/blood.v76.12.2462.2462
Schmid C, Kuball J, Bug G. Defining the Role of donor lymphocyte infusion in high-risk hematologic malignancies. J Clin Oncol. 2021;39:397–418. https://doi.org/10.1200/JCO.20.01719
doi: 10.1200/JCO.20.01719
Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T, et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia. 2013;27:1229–35. https://doi.org/10.1038/leu.2013.7
doi: 10.1038/leu.2013.7
Guillaume T, Malard F, Magro L, Labopin M, Tabrizi R, Borel C, et al. Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transpl. 2019;54:1815–26. https://doi.org/10.1038/s41409-019-0536-y
doi: 10.1038/s41409-019-0536-y
Amit O, Bar-On Y, Perets G, Atlas L, Shargian L, Yeshurun M, et al. Venetoclax and DLI for patients with early relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. A historical prospective multicenter trial. Blood. 2019;134:2018–2018. https://doi.org/10.1182/blood-2019-126999
doi: 10.1182/blood-2019-126999
Ueda M, Lazarus HM, Tomlinson B, Creger R, Kolk M, de Lima M, et al. Concurrent Use of Blinatumomab and Donor Lymphocyte Infusion (DLI) for treatment of relapsed precursor B Cell Acute Lymphoblastic Leukemia (pre B ALL) after Allogeneic Hematopoietic Cell Transplant (HCT). Biol Blood Marrow Transpl. 2016;22:S359–60. https://doi.org/10.1016/j.bbmt.2015.11.861
doi: 10.1016/j.bbmt.2015.11.861
Schuler E, Wagner-Drouet E-M, Ajib S, Bug G, Crysandt M, Dressler S, et al. Treatment of relapse after allogeneic hematopoietic stem cell transplantation with Venetoclax, Hypomethylating agents and DLI - a retrospective multi center study. Blood. 2019;134:4563–4563. https://doi.org/10.1182/blood-2019-125087
doi: 10.1182/blood-2019-125087
Theurich S, Malcher J, Wennhold K, Shimabukuro-Vornhagen A, Chemnitz J, Holtick U, et al. Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem- cell transplantation induces tumor-specific immunity and sustained clinical remission. J Clin Oncol. 2013;31:e59–63. https://doi.org/10.1200/JCO.2012.43.6832
doi: 10.1200/JCO.2012.43.6832
Tsirigotis P, Danylesko I, Gkirkas K, Shem-Tov N, Yerushalmi R, Stamouli M, et al. Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transpl. 2016;51:1313–7. https://doi.org/10.1038/bmt.2016.129
doi: 10.1038/bmt.2016.129
Sun W, Mo XD, Zhang XH, Xu LP, Wang Y, Yan CH, et al. Chemotherapy plus DLI for relapse after haploidentical HSCT: the biological characteristics of relapse influences clinical outcomes of acute leukemia patients. Bone Marrow Transpl. 2019;54:1198–207. https://doi.org/10.1038/s41409-018-0406-z
doi: 10.1038/s41409-018-0406-z
Cauchois R, Castagna L, Pagliardini T, Harbi S, Calmels B, Bramanti S, et al. Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haematological malignancies: a retrospective bicentric analysis of serial infusions of increasing doses of CD3 + cells. Br J Haematol. 2019;185:570–3. https://doi.org/10.1111/bjh.15544
doi: 10.1111/bjh.15544
Chabannon C, Kubal J, Bondanza A, Dazzi F, Pedrazzoli P, Toubert A, et al. Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies. Sci Transl Med. 2018;10. https://doi.org/10.1126/scitranslmed.aap9630 .
Castagna L, Valli V, Timofeeva I, Capizzuto R, Bramanti S, Mariotti J, et al. Feasibility and efficacy of CD45RA+ depleted donor lymphocytes infusion after haploidentical transplantation with post-transplantation cyclophosphamide in patients with hematological malignancies. Transpl Cell Ther. 2021;27:478.e1–478.e5. https://doi.org/10.1016/j.jtct.2021.03.010
doi: 10.1016/j.jtct.2021.03.010
Devillier R, Calmels B, Guia S, Taha M, Fauriat C, Mfarrej B, et al. Phase I trial of prophylactic donor-derived IL-2-activated NK cell infusion after allogeneic hematopoietic stem cell transplantation from a matched sibling donor. Cancers. 2021;13:2673.
doi: 10.3390/cancers13112673